Seres Therapeutics (NASDAQ:MCRB) Price Target Cut to $12.00

Seres Therapeutics (NASDAQ:MCRBGet Rating) had its price target dropped by analysts at Chardan Capital from $16.00 to $12.00 in a research report issued to clients and investors on Thursday, The Fly reports. Chardan Capital’s price objective indicates a potential upside of 140.96% from the stock’s current price.

A number of other equities research analysts also recently issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and set a $25.00 price target on shares of Seres Therapeutics in a research note on Wednesday, June 8th. Piper Sandler decreased their price target on shares of Seres Therapeutics from $32.00 to $7.00 and set an “overweight” rating on the stock in a research note on Monday, May 23rd. Finally, Jefferies Financial Group raised shares of Seres Therapeutics to a “buy” rating in a research note on Wednesday, June 8th.

Seres Therapeutics Trading Up 2.0 %

MCRB stock opened at $4.98 on Thursday. Seres Therapeutics has a one year low of $2.50 and a one year high of $11.69. The company’s fifty day moving average price is $3.60 and its 200-day moving average price is $5.44. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.20 and a quick ratio of 3.20.

Seres Therapeutics (NASDAQ:MCRBGet Rating) last released its earnings results on Wednesday, May 4th. The biotechnology company reported ($0.61) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.05). Seres Therapeutics had a negative return on equity of 79.71% and a negative net margin of 75.48%. The company had revenue of $1.49 million during the quarter, compared to analysts’ expectations of $7.11 million. During the same period last year, the firm posted ($0.39) EPS. Research analysts forecast that Seres Therapeutics will post -2.28 EPS for the current year.

Insider Buying and Selling at Seres Therapeutics

In other news, major shareholder Health Ltp Fund Ge Nutritional acquired 8,738,243 shares of the business’s stock in a transaction on Tuesday, July 5th. The shares were acquired at an average price of $3.15 per share, for a total transaction of $27,525,465.45. Following the completion of the transaction, the insider now directly owns 5,875,711 shares of the company’s stock, valued at approximately $18,508,489.65. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 3.00% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Russell Investments Group Ltd. grew its holdings in shares of Seres Therapeutics by 414.3% in the fourth quarter. Russell Investments Group Ltd. now owns 94,125 shares of the biotechnology company’s stock worth $782,000 after purchasing an additional 75,825 shares during the last quarter. Janney Montgomery Scott LLC grew its holdings in shares of Seres Therapeutics by 62.2% in the fourth quarter. Janney Montgomery Scott LLC now owns 43,300 shares of the biotechnology company’s stock worth $361,000 after purchasing an additional 16,600 shares during the last quarter. Qube Research & Technologies Ltd bought a new position in shares of Seres Therapeutics in the fourth quarter worth about $1,205,000. DekaBank Deutsche Girozentrale grew its holdings in shares of Seres Therapeutics by 3.1% in the fourth quarter. DekaBank Deutsche Girozentrale now owns 67,000 shares of the biotechnology company’s stock worth $577,000 after purchasing an additional 2,000 shares during the last quarter. Finally, New York State Common Retirement Fund grew its holdings in shares of Seres Therapeutics by 29.8% in the fourth quarter. New York State Common Retirement Fund now owns 49,856 shares of the biotechnology company’s stock worth $415,000 after purchasing an additional 11,449 shares during the last quarter. Institutional investors own 80.70% of the company’s stock.

Seres Therapeutics Company Profile

(Get Rating)

Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI).

Featured Articles

The Fly logo

Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.